LONDON (Alliance News) - Hutchison China MediTech Ltd said Friday its prescription drug joint venture, Shanghai Hutchison Pharmaceuticals Ltd, has been granted an invention patent in China for a formulation of its drug for the treatment of cardiovascular diseases.
The patent covers the formulation of the She Xiang Bao Xin pill until 2029. Sales of the drug in 2014 were USD138.8 million, compared to USD123.6 million in 2013, and the drug represents around 90% of the joint venture's current sales.
"The grant of this new patent will allow for this important cardiovascular therapy, to maintain its proprietary position in China for many years to come," said Chief Executive Officer Christian Hogg in a statement.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Hutchmed (HCM)